Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
2.
Article Dans Anglais | WPRIM | ID: wpr-16398

Résumé

Recent advances in chemotherapy have led to increased survival rates for patients with hematologic malignancies. However, standard chemotherapies, including alkylating agents for non-Hodgkin lymphoma, could induce therapy-related myeloid neoplasms (t-MNs), a group of disorders categorized by the World Health Organization in 2008. Here, we report a case of coexistence of bone marrow (BM)-involved refractory marginal zone B-cell lymphoma (MZL) and therapy-related myelodysplastic syndrome (t-MDS). Simultaneous presence of refractory lymphoma and t-MN in the BM is rare, and this is the first report in Korea. The patient received allogeneic hematopoietic stem cell transplantation (HSCT) to cure both the MZL and t-MDS. Since the HSCT, he has been stable for 21 months without any evidence of recurrence.


Sujets)
Humains , Agents alcoylants , Moelle osseuse , Traitement médicamenteux , Tumeurs hématologiques , Transplantation de cellules souches hématopoïétiques , Corée , Lymphomes , Lymphome B de la zone marginale , Lymphome malin non hodgkinien , Syndromes myélodysplasiques , Récidive , Taux de survie , Organisation mondiale de la santé
SÉLECTION CITATIONS
Détails de la recherche